Reimagine Medicine | Novartis United States of America

Media Release
Jul 09, 2014
Novartis announces NEJM publication of two pivotal Phase III secukinumab studies demonstrating statistically significant skin clearance in psoriasis patients
Media Release
Jul 07, 2014
Novartis personalized cell therapy CTL019 receives FDA Breakthrough Therapy designation
Media Release
Jun 01, 2014
Pivotal data for Novartis' investigational compound LDE225 show marked tumor responses in advanced basal cell carcinoma
Media Release
May 22, 2014
Novartis presents key advances in cancer research at ASCO and EHA from four new pivotal studies in lung, blood and skin cancers
Media Release
May 05, 2014
Novartis drug Signifor® LAR shows superior efficacy in acromegaly patients not controlled on first generation somatostatin analogues
Media Release
Apr 23, 2014
Novartis recognized as top ranking company in the US on DiversityInc Top 50 Companies for Diversity list
Media Release
Mar 22, 2014
Novartis reports new Phase III data showing secukinumab (AIN457) improved moderate-to-severe plaque psoriasis in patients
Media Release
Mar 21, 2014
Novartis Announces FDA Approval of Xolair® (omalizumab) for Chronic Idiopathic Urticaria (CIU), a Form of Chronic Hives
Media Release
Jan 09, 2014
Novartis Pharmaceuticals Corporation stands behind medication adherence activities and reaffirms commitment to patient safety
Media Release
Dec 07, 2013
Novartis highlights research on investigational, personalized T cell therapy CTL019 in patients with forms of acute and chronic leukemia
Media Release
Oct 28, 2013
Novartis Hosts Competition to Create Novel Mobile Solutions for Heart Failure Caregivers
Media Release
Sep 23, 2013
Novartis announces new data on the effects of investigational RLX030 on kidney blood flow in chronic heart failure patients

‹ Previous page
1
…
19
20
21
22
23
24
25
…
50
› Next page